Video Library

GRACE sat down with Dr. Marco Ruiz to discuss information regarding when and who to refer for hematopoietic cell transplantation (HCT) (¿Cuándo y para quién se recomienda el trasplante de células hematopoyéticas (TCH)?). Stay tuned for more on our continuing video series with our Spanish speaking

GRACE sat down with Dr. Marco Ruiz to discuss information regarding acute myeloid leukemia (AML) in elderly patients (Leucemia aguda mieloide (LMA) en la población de tercera edad). Stay tuned for more on our continuing video series with our Spanish speaking faculty on updates in blood cancer

GRACE sat down with Dr. Marco Ruiz to discuss information regarding inhibitory molecules like the programmed cell death protein 1 (PD1) and its ligand (PDL1), and if they are active in lymphoma and in chronic lymphocytic leukemia (¿Están activos moléculas inhibitorias como el de la muerte programada

GRACE sat down with Dr. Marco Ruiz to discuss information regarding the role of surveillance imaging in indolent lymphomas and chronic lymphocytic leukemia (CLL) (¿Cuál es el rol de vigilancia imagenológica en linfomas indolentes y en la leucemia crónica linfocítica?). Stay tuned for more on our

GRACE sat down with Dr. Marco Ruiz to discuss information regarding all diffuse large B-cell lymphoma (DLBCL) and are they made equally ("¿Todos los linfomas difusos de linfocitos B (DLBCL) están hechos iguales?"). Stay tuned for more on our continuing video series with our Spanish speaking faculty

Dr. Jared Weiss, Vice President of GRACE and Associate Professor at UNC-Chapel Hill in Clinical Research, and the Thoracic Oncology Program at UNC Lineberger, discusses First Line EGFR-Based Therapy For Advanced Squamous Non-Small Cell Lung Cancer (NSCLC).

GRACE is pleased to present updates in blood cancer treatments for our Spanish Blood Cancer Library with Dr. Marco Ruiz. Dr. Ruiz shares information regarding Chronic Lymphocytic Leukemia & Non-Hodgkin Lymphoma, (Leucemia crónica linfocítica y linfoma no Hodgkin)., specifically "Are all diffuse

GRACE sat down with Dr. Marco Ruiz to discuss information regarding the chimeric T cell receptors treatment against tumoral antigens (CAR-T) and how it works (¿Cuál es la terapia de receptores de linfocitos T quiméricos contra antígenos tumorales (CAR-T)? y ¿Cómo funciona ?). Stay tuned for more on

For this video on the risks and benefits of Ibrutinib Idelalisib, GRACE sat down with Marco Ruiz, MD, an oncologist at Memorial Cancer Institute specializing in hematologic or blood cancers, including leukemia, lymphoma, myelodysplastic syndrome (MDS) and myelofibrosis. He is also an experienced

Drs. H. Jack West, Matthew Gubens, and Jyoti Patel, gathered post ASCO 2017 to discuss new information regarding lung cancer. In this video, the doctors discuss Dacomitinib Beats Iressa as First Line Treatment for EGFR Mutation-Positive NSCLC: New Option or Too Little Too Late?

Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University discusses Liquid Biopsies for EGFR.

Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University discusses treatment options for acquired resistance to EGFR TKIs: T790M-negative disease.

Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University discusses treatment options for acquired resistance to EGFR TKIs: T790M-positive disease.

Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University discusses current standards and options for first-line treatment of EGFR mutation-positive NSCLC.

Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University joined GRACE to discuss different types of EGFR mutations and their potential clinical implications.